Biotechnology

A novel case study reveals how targeted chemotherapy delivery is outsmarting stubborn tumors, highlighting a metabolic victory even when size remains unchanged.

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

A new FDA-approved therapy from Boehringer Ingelheim and a liquid biopsy from Guardant Health offer the first targeted initial treatment for HER2-mutant NSCLC.

RenX just wiped $7M of debt in a savvy insider deal. It’s more than a balance sheet fix—it’s a calculated bet on a tech-driven, sustainable future.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

Major academic centers no longer hold a monopoly on medical breakthroughs. A look at how community networks are democratizing cutting-edge cancer research.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

New data on an all-oral combo therapy for AML shows remarkable efficacy, offering new hope for patients and cementing Syndax's competitive advantage.

Relmada Therapeutics poaches a Sage neurosteroid expert for its sepranolone program. A look at the strategic rationale behind a move that signals big ambitions.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

Stunning head-to-head trial data shows Takeda's zasocitinib is 2.5x more effective than its rival, signaling a major market disruption and validating a landmark deal.

Shanghai is launching a massive tech festival in 2026. Is it a genuine gateway for global firms or a carefully curated showcase of China's industrial might?

A key clinical trial completion in Japan signals a major shift in prostate cancer care, heralding the arrival of advanced PSMA-targeted theranostics.

A Swedish firm's novel cell therapy is the first of its kind in Europe, challenging the grim prognosis of pancreatic cancer and testing a new model for biotech.

Nancy Torres analyzes Héma-Québec's summer tour, revealing a sophisticated strategy to combat supply chain risks, secure plasma independence, and diversify its donor base.

Hyundai Bioscience offers a free drug for an untreatable Ebola strain. It's a bold humanitarian gesture, and a masterclass in strategic maneuvering.

Athletes are ditching complex supplement stacks for all-in-one EAA formulas. We explore the science and the industry shift fueling this minimalist movement.

Aethlon Medical is advancing a device to filter pathogens from the bloodstream, viewing it as a firewall for the body's internal communication network.

As Kewaunee Scientific preps its year-end report, all eyes are on whether its bold Nu Aire acquisition can translate revenue gains into long-term profit.

A new partnership between health tech pioneer Snke and biotech firm Precision NeuroMed aims to build a data-driven roadmap for treating neurological diseases.